Featured Research

from universities, journals, and other organizations

Long term results of trial for patients with liver metastases from colorectal cancer

Date:
November 6, 2013
Source:
European Organisation for Research and Treatment of Cancer
Summary:
The authors of a new study conclude that perioperative chemotherapy with FOLFOX4 should remain the reference treatment for patients with liver metastases from colorectal cancer.

Long term results of the randomized phase III EORTC intergroup trial 40983 were recently reported in The Lancet Oncology. The observed 4.1% difference in overall survival at five years for patients with initially resectable liver metastases from colorectal cancer was not significant for perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) compared with surgery alone. Earlier results of this same trial had shown that perioperative chemotherapy with FOLFOX4 increases progression-free survival (the primary endpoint) compared with surgery alone for these patients. Overall survival was a secondary endpoint, and the trial was not initially powered to compare overall survival in the two groups. Consequently, the authors conclude that perioperative chemotherapy with FOLFOX4 should remain the reference treatment for this population of patients.

Prof. Bernard Nordlinger of the Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Université de Versailles, Boulogne- Billancourt, France, and member of the EORTC Gastrointestinal Tract Cancer Group says, "Surgery is currently the only potentially curative treatment for resectable liver metastases, yet only 15-20% of patients with hepatic metastases are initially eligible for a radical surgical treatment. Furthermore, less than one half of patients who do receive such treatment achieve 5-year survival after resection. This is likely due to the presence of residual disease, so it is thought that adjuvant chemotherapy could help these patients."

EORTC intergroup trial 40983 recruited 364 patients between the ages of 18-80 years with colorectal cancer and up to four liver metastases. Patients were randomly assigned to either perioperative FOLFOX4, 182 patients, or surgery alone, 182 patients. Of these, eleven patients per group were deemed to be ineligible.

At a median follow-up of 8.5 years (Interquartile range 7•6 years-9•5 years), 59% of all randomized patients in the perioperative chemotherapy group had died as opposed to 63% in the surgery alone group (Hazard ratio 0.88, 95% confidence interval (CI) 0•68-1•14; p=0•34). Median overall survival was 61.3 months (95% CI 51.0-83.4) for patients receiving perioperative chemotherapy and 54.3 months (95% CI 41.9-79.4) for those receiving surgery alone, while the 5-year overall survival was 51.2% (95% CI 43.6-58.3) in the perioperative chemotherapy group and 47.8% (95% CI 40.3-55.0) in the surgery-only group. In eligible patients (171 per group), estimated 5-year overall survival was 52.4% in the perioperative chemotherapy group versus 48.3% in the surgery alone group.

Five patients (two patients in the perioperative chemotherapy group and three in the surgery-only group) passed away due to complications from surgery. One additional death in the perioperative chemotherapy group was possibly a result of toxicity from the protocol treatment.


Story Source:

The above story is based on materials provided by European Organisation for Research and Treatment of Cancer. Note: Materials may be edited for content and length.


Journal Reference:

  1. Bernard Nordlinger, Halfdan Sorbye, Bengt Glimelius, Graeme J Poston, Peter M Schlag, Philippe Rougier, Wolf O Bechstein, John N Primrose, Euan T Walpole, Meg Finch-Jones, Daniel Jaeck, Darius Mirza, Rowan W Parks, Murielle Mauer, Erik Tanis, Eric Van Cutsem, Werner Scheithauer, Thomas Gruenberger. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. The Lancet Oncology, 2013; 14 (12): 1208 DOI: 10.1016/S1470-2045(13)70447-9

Cite This Page:

European Organisation for Research and Treatment of Cancer. "Long term results of trial for patients with liver metastases from colorectal cancer." ScienceDaily. ScienceDaily, 6 November 2013. <www.sciencedaily.com/releases/2013/11/131106114029.htm>.
European Organisation for Research and Treatment of Cancer. (2013, November 6). Long term results of trial for patients with liver metastases from colorectal cancer. ScienceDaily. Retrieved April 20, 2014 from www.sciencedaily.com/releases/2013/11/131106114029.htm
European Organisation for Research and Treatment of Cancer. "Long term results of trial for patients with liver metastases from colorectal cancer." ScienceDaily. www.sciencedaily.com/releases/2013/11/131106114029.htm (accessed April 20, 2014).

Share This



More Health & Medicine News

Sunday, April 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Nine-Month-Old Baby Can't Open His Mouth

Nine-Month-Old Baby Can't Open His Mouth

Newsy (Apr. 19, 2014) — Nine-month-old Wyatt Scott was born with a rare disorder called congenital trismus, which prevents him from opening his mouth. Video provided by Newsy
Powered by NewsLook.com
'Holy Grail' Of Weight Loss? New Find Could Be It

'Holy Grail' Of Weight Loss? New Find Could Be It

Newsy (Apr. 18, 2014) — In a potential breakthrough for future obesity treatments, scientists have used MRI scans to pinpoint brown fat in a living adult for the first time. Video provided by Newsy
Powered by NewsLook.com
Little Progress Made In Fighting Food Poisoning, CDC Says

Little Progress Made In Fighting Food Poisoning, CDC Says

Newsy (Apr. 18, 2014) — A new report shows rates of two foodborne infections increased in the U.S. in recent years, while salmonella actually dropped 9 percent. Video provided by Newsy
Powered by NewsLook.com
Scientists Create Stem Cells From Adult Skin Cells

Scientists Create Stem Cells From Adult Skin Cells

Newsy (Apr. 17, 2014) — The breakthrough could mean a cure for some serious diseases and even the possibility of human cloning, but it's all still a way off. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins